Combination therapies aim to target multiple pathways simultaneously to prevent the emergence of resistant cell populations. By using a combination of drugs that target different mechanisms, the likelihood of cancer cells developing resistance can be reduced. For example, combining a tyrosine kinase inhibitor with a monoclonal antibody can be more effective than either therapy alone.
